Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003019957> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2003019957 endingPage "85" @default.
- W2003019957 startingPage "78" @default.
- W2003019957 abstract "This phase II study (n = 20) aimed to evaluate type, severity and duration of side-effects and efficacy following subcutaneous (SC) alemtuzumab, without dose-escalation, in advanced-stage relapsed chronic lymphocytic leukaemia (CLL) patients. Alemtuzumab 30 and 3 mg was administered SC simultaneously day 1, followed by 30 mg three times per week. Injection-site-reactions were recorded every 6-24 h until resolved using National Cancer Institute criteria and a new skin toxicity subscale. The first doses of 30 mg and 3 mg produced injection-site-reactions (all but one were grade 1/2) in 13/20 and 9/20 patients, respectively. The second dose (on day 3) resulted in skin-reactions in 10/20 patients and the third, fourth, fifth and sixth injections produced reactions in 6/20, 1/20, 2/20 and 0/20 patients, respectively. Mild flu-like symptoms occurred during week 1 in 10/20 patients. All side-effects had subsided by the sixth dose. 15/20 patients (75%) responded (12 partial responses, three complete responses) with a median time-to-treatment-failure of 20 months. Symptomatic cytomegalovirus-reactivation occurred in 6/20 patients. Two deaths occurred: one bacterial pneumonia and one adenovirus-infection. The present study showed how to assess cutaneous-toxicity in detail and that 30 mg alemtuzumab SC administered upfront was well tolerated. Optimized alemtuzumab therapy in properly selected patients may result in high efficacy even in advanced CLL. Our results need to be confirmed in extended studies." @default.
- W2003019957 created "2016-06-24" @default.
- W2003019957 creator A5008546299 @default.
- W2003019957 creator A5043417410 @default.
- W2003019957 creator A5047631289 @default.
- W2003019957 creator A5049924304 @default.
- W2003019957 creator A5060073254 @default.
- W2003019957 creator A5065902991 @default.
- W2003019957 creator A5089373395 @default.
- W2003019957 date "2008-12-09" @default.
- W2003019957 modified "2023-10-18" @default.
- W2003019957 title "Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia" @default.
- W2003019957 cites W1972577971 @default.
- W2003019957 cites W2012721290 @default.
- W2003019957 cites W2016973656 @default.
- W2003019957 cites W2019779933 @default.
- W2003019957 cites W2043607649 @default.
- W2003019957 cites W2099145932 @default.
- W2003019957 cites W2102012339 @default.
- W2003019957 cites W2102505853 @default.
- W2003019957 cites W2116022383 @default.
- W2003019957 cites W2142099365 @default.
- W2003019957 cites W2143749371 @default.
- W2003019957 cites W2168724841 @default.
- W2003019957 cites W2169167811 @default.
- W2003019957 cites W2550265197 @default.
- W2003019957 cites W2588472384 @default.
- W2003019957 cites W60865865 @default.
- W2003019957 cites W83807906 @default.
- W2003019957 doi "https://doi.org/10.1111/j.1365-2141.2008.07451.x" @default.
- W2003019957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19016731" @default.
- W2003019957 hasPublicationYear "2008" @default.
- W2003019957 type Work @default.
- W2003019957 sameAs 2003019957 @default.
- W2003019957 citedByCount "32" @default.
- W2003019957 countsByYear W20030199572012 @default.
- W2003019957 countsByYear W20030199572013 @default.
- W2003019957 countsByYear W20030199572014 @default.
- W2003019957 countsByYear W20030199572015 @default.
- W2003019957 countsByYear W20030199572017 @default.
- W2003019957 countsByYear W20030199572022 @default.
- W2003019957 crossrefType "journal-article" @default.
- W2003019957 hasAuthorship W2003019957A5008546299 @default.
- W2003019957 hasAuthorship W2003019957A5043417410 @default.
- W2003019957 hasAuthorship W2003019957A5047631289 @default.
- W2003019957 hasAuthorship W2003019957A5049924304 @default.
- W2003019957 hasAuthorship W2003019957A5060073254 @default.
- W2003019957 hasAuthorship W2003019957A5065902991 @default.
- W2003019957 hasAuthorship W2003019957A5089373395 @default.
- W2003019957 hasConcept C126322002 @default.
- W2003019957 hasConcept C141071460 @default.
- W2003019957 hasConcept C146357865 @default.
- W2003019957 hasConcept C151730666 @default.
- W2003019957 hasConcept C2778496288 @default.
- W2003019957 hasConcept C2779015954 @default.
- W2003019957 hasConcept C2911091166 @default.
- W2003019957 hasConcept C29730261 @default.
- W2003019957 hasConcept C71924100 @default.
- W2003019957 hasConcept C86803240 @default.
- W2003019957 hasConcept C90924648 @default.
- W2003019957 hasConceptScore W2003019957C126322002 @default.
- W2003019957 hasConceptScore W2003019957C141071460 @default.
- W2003019957 hasConceptScore W2003019957C146357865 @default.
- W2003019957 hasConceptScore W2003019957C151730666 @default.
- W2003019957 hasConceptScore W2003019957C2778496288 @default.
- W2003019957 hasConceptScore W2003019957C2779015954 @default.
- W2003019957 hasConceptScore W2003019957C2911091166 @default.
- W2003019957 hasConceptScore W2003019957C29730261 @default.
- W2003019957 hasConceptScore W2003019957C71924100 @default.
- W2003019957 hasConceptScore W2003019957C86803240 @default.
- W2003019957 hasConceptScore W2003019957C90924648 @default.
- W2003019957 hasIssue "1" @default.
- W2003019957 hasLocation W20030199571 @default.
- W2003019957 hasLocation W20030199572 @default.
- W2003019957 hasOpenAccess W2003019957 @default.
- W2003019957 hasPrimaryLocation W20030199571 @default.
- W2003019957 hasRelatedWork W139966500 @default.
- W2003019957 hasRelatedWork W2026007874 @default.
- W2003019957 hasRelatedWork W2092270052 @default.
- W2003019957 hasRelatedWork W2160416386 @default.
- W2003019957 hasRelatedWork W2274661527 @default.
- W2003019957 hasRelatedWork W2316222817 @default.
- W2003019957 hasRelatedWork W2344434792 @default.
- W2003019957 hasRelatedWork W2936650130 @default.
- W2003019957 hasRelatedWork W3040604607 @default.
- W2003019957 hasRelatedWork W4285536504 @default.
- W2003019957 hasVolume "144" @default.
- W2003019957 isParatext "false" @default.
- W2003019957 isRetracted "false" @default.
- W2003019957 magId "2003019957" @default.
- W2003019957 workType "article" @default.